Výsledky vyhledávání - "Hanna Kelly Sanoff"

A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC)

Autor: Ashwin Somasundaram, Paul R. Helft, William Proctor Harris, Hanna Kelly Sanoff, Guy E. Johnson, Menggang Yu, Matthew Johnson, Bert O'Neil, Autumn Jackson McRee

Publikováno v: Journal of Clinical Oncology. 41:534-534

534 Background: HCC is an aggressive cancer as a sequela of cirrhosis. For pts with no extrahepatic metastases and well-compensated liver function, Y90 radioembolization is a therapeutic option. However, high-risk patients with macrovascular invasion

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9cfa48388ce946cef3b92ed406388bb4
https://doi.org/10.1200/jco.2023.41.4_suppl.534

Zobrazit plný text záznamu

Comparative effectiveness of trimodal therapy versus definitive chemoradiation in older adults with locally advanced esophageal cancer

Autor: Charles Gaber, Nicholas J. Shaheen, Jessie K. Edwards, Robert S Sandler, Hazel Nichols, Hanna Kelly Sanoff, Jennifer Leigh Lund

Publikováno v: Journal of Clinical Oncology. 40:e16093-e16093

e16093 Background: The comparative effectiveness of trimodal therapy versus definitive chemoradiation for older adults with locally advanced esophageal cancer is uncertain. Only two randomized trials have considered this comparison, and older adults

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d322aead0a017ecf0721e49e010c781a
https://doi.org/10.1200/jco.2022.40.16_suppl.e16093

Zobrazit plný text záznamu

Myopenia and mechanisms of toxicity in older adults with colorectal cancer (CRC): The M&M study (WF-1806)

Autor: Grant Richard Williams, Smita Bhatia, Heidi D. Klepin, Hanna Kelly Sanoff, Hyman B. Muss, Mustafa Al-Obaidi, Christian Harmon, Joshua Richman, Emily Van Meter Dressler, Mark Allen O'Rourke, Kathryn E. Weaver, Glenn Jay Lesser

Publikováno v: Journal of Clinical Oncology. 40:TPS3640-TPS3640

TPS3640 Background: CRC is the 2nd most common cause of cancer death in the US, and nearly 60% of CRC cases occur among older adults. There is a critical unmet need to understand the underlying cause(s) of observed variability in chemotherapy toxicit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::71e4c68d38dcfda4df7e4472f2d62f7a
https://doi.org/10.1200/jco.2022.40.16_suppl.tps3640

Zobrazit plný text záznamu

A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC) with preserved liver function

Autor: Autumn Jackson McRee, Paul R. Helft, William Proctor Harris, Hanna Kelly Sanoff, Matthew Johnson, Menggang Yu, Bert O'Neil

Publikováno v: Journal of Clinical Oncology. 40:422-422

422 Background: HCC is an aggressive cancer that is challenging to treat due to the concomitant diagnosis of cirrhosis. For HCC pts with no extrahepatic metastases and well-compensated liver function, Y90 radioembolization is a standard therapy. In o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e825d76c6add698f2a0fde4879df6c98
https://doi.org/10.1200/jco.2022.40.4_suppl.422

Zobrazit plný text záznamu

Integrated approach to collecting patient reported toxicities in a colorectal cancer trial

Autor: Jacquelyne Janean Gaddy, Hanna Kelly Sanoff, Allison Mary Deal, Ethan Basch, William Allen Wood

Publikováno v: Journal of Clinical Oncology. 40:51-51

51 Background: Understanding the toxicities experienced by patients treated with advanced CRC is critical when considering appropriate dose modifications, standard drug dosing, and quality of life. A workflow that makes available Patient Reported Out

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1deb4c7346e6e1e325b1a93c9c814d0b
https://doi.org/10.1200/jco.2022.40.4_suppl.051

Zobrazit plný text záznamu

Phase II single-arm study of palbociclib and cetuximab rechallenge in KRAS/NRAS/BRAF wild-type (KRAS WT) metastatic colorectal cancer (mCRC) patients (pts)

Autor: Jonathan D Sorah, Dominic T. Moore, Matthew Reilley, Mohamed E. Salem, Hanna Kelly Sanoff, Tammy Triglianos, Autumn Jackson McRee, Michael Sangmin Lee

Publikováno v: Journal of Clinical Oncology. 40:88-88

88 Background: Cetuximab is a monoclonal antibody (mAb) targeting the epidermal growth factor receptor (EGFR) and is given alone or in combination with chemotherapy in the 60% of mCRC that are KRAS WT. Unfortunately, resistance inevitably develops, w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ea0919fcd61f155e5f2b954652be2a67
https://doi.org/10.1200/jco.2022.40.4_suppl.088

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání